The abstract is read at the publisher; the summary is JClub's.
Two-spacer bio-reinforced cyclodialysis achieved greater 12-month IOP reduction than one spacer in 310 CREST study eyes, with an unadjusted 2.52 mmHg difference.
- Why it matters: It addresses whether adding a second acellular scleral allograft spacer provides incremental IOP lowering beyond a single spacer, a question not previously reported.
- What they did: In a prospective multicenter real-world CREST analysis of 310 eyes undergoing combined phacoemulsification and bio-reinforced cyclodialysis, investigators compared one spacer (n=170) versus two (n=140) using unadjusted tests, baseline-adjusted regression, 1:1 propensity matching, doubly robust overlap weighting, and site-adjusted models.
- The result: The IOP reduction advantage persisted after propensity matching (2.36 mmHg) and overlap weighting (1.99 mmHg) but attenuated after accounting for enrolling site (0.86 mmHg; p=0.080), with no difference within sites; medication and secondary procedure rates were similar.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.